TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23226534

Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study: 20220605

Group type: EXPERIMENTAL
Intervention: Gua-Sha therapy (scraping therapy)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Traditional breast care (massage and heating)
Number of subjects: 54
Study: 18560342

Group type: EXPERIMENTAL
Intervention: Phytoestrogens therapy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 16326677

Group type: EXPERIMENTAL
Intervention: Remifentanil 0.03 microg.kg(‐1).min(‐1)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Remifentanil 0.06 microg.kg(‐1).min(‐1)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Remifentanil 0.12 microg.kg(‐1).min(‐1)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Remifentanil 0.25 microg.kg(‐1).min(‐1)
Number of subjects: 58
Study: 12183768

Group type: EXPERIMENTAL
Intervention: Ectatic infrarenal aorta (2.5‐2.9 cm diameter)
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Surveillance protocol (repeat ultrasound)
Number of subjects: 223
Study: 9890490

Group type: EXPERIMENTAL
Intervention: Combination of pentifylline (800 mg) and nicotinic acid (200 mg) daily
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Piracetam (2.4 g daily)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 7675959

Group type: EXPERIMENTAL
Intervention: 0.50 ml 95% USP alcohol/kg body weight
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.75 ml 95% USP alcohol/kg body weight
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1.00 ml 95% USP alcohol/kg body weight
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.135 ml 95% USP alcohol/kg body weight (active placebo)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sober condition
Number of subjects: 0
Study: 2288827

Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 92511

Group type: EXPERIMENTAL
Intervention: 700 CCA units of purified subunit vaccine
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: 1,400 CCA units of whole-virus vaccine
Number of subjects: 186

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: 700 CCA units of whole-virus vaccine
Number of subjects: 186
Study: 30523381

Group type: EXPERIMENTAL
Intervention: Celecoxib (C- group)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Capeox without Celecoxib (C+ group)
Number of subjects: 81
Study: 28706173

Group type: EXPERIMENTAL
Intervention: Self-reflection program (6 sessions over 6 weeks)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 38
Study: 26467994

Group type: EXPERIMENTAL
Intervention: QoL pathway intervention with tailored QoL diagnosis and therapy, including QoL profile and expert report with treatment recommendations.
Number of subjects: 220

Group type: COMPARATOR
Intervention: Routine follow-up care attending the guideline recommendations for colorectal cancer without profile or expert report.
Number of subjects: 220
Study: 23406545

Group type: EXPERIMENTAL
Intervention: NK₁ receptor antagonist aprepitant
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 19962291

Group type: EXPERIMENTAL
Intervention: Wormwood (Artemisia absinthium) 3x750mg dried powdered for 6 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Wormwood (Artemisia absinthium)
Number of subjects: 20
Study: 18244958

Group type: EXPERIMENTAL
Intervention: Structured three session programme at age 8‐15 months, co‐led by well child providers and a parenting expert.
Number of subjects: 733

Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 733
Study: 16864616

Group type: EXPERIMENTAL
Intervention: Biventricular pacing
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Right ventricular (RV) pacing
Number of subjects: 1200
Study: 14638493

Group type: EXPERIMENTAL
Intervention: 0.25% resiquimod
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: 0.05% resiquimod
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: 0.01% resiquimod
Number of subjects: 41

Group type: COMPARATOR
Intervention: Vehicle gel (control)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: All resiquimod doses
Number of subjects: 41
Study: 10651836

Group type: EXPERIMENTAL
Intervention: Hyperinsulinemic euglycemic clamp with infusion of 20 glucose (30% enriched with 13C‐1‐glucose)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Use of 13C MRS to determine total muscular glucose content
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Treatment with troglitazone
Number of subjects: 8
Study: 9079411

Group type: EXPERIMENTAL
Intervention: Recombinant follicle stimulating hormone (rFSH; Puregon)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Urinary FSH or human menopausal gonadotrophins
Number of subjects: 1000
Study: 1298221

Group type: COMPARATOR
Intervention: Carbamazepine
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Valproate
Number of subjects: 480
Study: 6575025

Group type: EXPERIMENTAL
Intervention: Conventional APF gel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thixotropic gel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pluronic-based fluoride gel
Number of subjects: 0
Study: 30077128

Group type: EXPERIMENTAL
Intervention: Microprocessor-controlled knee
Number of subjects: 50

Group type: COMPARATOR
Intervention: Non-microprocessor-controlled knee
Number of subjects: 50
Study: 28167467

Group type: EXPERIMENTAL
Intervention: Dermidoc cream
Number of subjects: 100

Group type: COMPARATOR
Intervention: PolymixinB-bacitrin ointment
Number of subjects: 100
Study: 26329480

Group type: EXPERIMENTAL
Intervention: pH 4 water-in-oil emulsion
Number of subjects: 40
Study: 23312684

Group type: EXPERIMENTAL
Intervention: Left lateral position
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Prone position
Number of subjects: 19

Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 19
Study: 21908986

Group type: EXPERIMENTAL
Intervention: Jackknife position
Number of subjects: 40

Group type: COMPARATOR
Intervention: Prone position
Number of subjects: 40
Study: 18469232

Group type: EXPERIMENTAL
Intervention: Low-calorie diet (LCD) providing 800 kcal/d
Number of subjects: 147
Study: 16565030

Group type: EXPERIMENTAL
Intervention: Four interviews and dialogues about pain with a female doctor (Group A)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Usual consultations with a male doctor (Group B)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 45
Study: 14743958

Group type: EXPERIMENTAL
Intervention: Reduced iron
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Electrolytic iron
Number of subjects: 32

Group type: COMPARATOR
Intervention: Ferrous sulphate (FeSO4)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Comparison between reduced and electrolytic iron
Number of subjects: 32
Study: 10955337

Group type: EXPERIMENTAL
Intervention: Health educational and exercise program (6 weekly sessions of 2 hours)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 105
Study: 8962564

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 1362205

Group type: EXPERIMENTAL
Intervention: Proglumide (15 mg/day)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 2413282

Group type: EXPERIMENTAL
Intervention: Verapamil administered orally (160 mg) before cytostatic treatment
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Verapamil administered orally (160 mg) after cytostatic treatment
Number of subjects: 9
Study: 31010904

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 29153933

Group type: EXPERIMENTAL
Intervention: Bronchial window
Number of subjects: 130

Group type: COMPARATOR
Intervention: Mediastinal window
Number of subjects: 130
Study: 27467290

Group type: EXPERIMENTAL
Intervention: Training program for catheterization
Number of subjects: 350

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 350
Study: 24403824

Group type: EXPERIMENTAL
Intervention: Rapid artificial cardiac pacing (RACP)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Sodium nitroprusside (SNP)
Number of subjects: 168
Study: 22002482

Group type: EXPERIMENTAL
Intervention: Follow-on formula with polydextrose and galactooligosaccharides (PDX/GOS)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Cow's‐milk‐based follow‐on formula (control)
Number of subjects: 133
Study: 20152241

Group type: EXPERIMENTAL
Intervention: Biolimus-eluting stents (n = 857)
Number of subjects: 1707

Group type: COMPARATOR
Intervention: Sirolimus-eluting stents (n = 850)
Number of subjects: 1707

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 1707
Study: 18714713

Group type: EXPERIMENTAL
Intervention: Access to women for screening in a randomized clinical trial
Number of subjects: 4131

Group type: EXPERIMENTAL
Intervention: Screening for study participation
Number of subjects: 4131
Study: 16908215

Group type: EXPERIMENTAL
Intervention: 19-lesson (9-month) intervention program to reduce TV viewing time
Number of subjects: 164
Study: 14600516

Group type: EXPERIMENTAL
Intervention: Simplified maintenance therapy (SMT)
Number of subjects: 1449

Group type: EXPERIMENTAL
Intervention: Abacavir (part of SMT)
Number of subjects: 1449

Group type: EXPERIMENTAL
Intervention: Efavirenz (part of SMT)
Number of subjects: 1449

Group type: EXPERIMENTAL
Intervention: Nevirapine (part of SMT)
Number of subjects: 1449

Group type: COMPARATOR
Intervention: Continued protease inhibitor (PI) therapy
Number of subjects: 1449
Study: 10912659

Group type: EXPERIMENTAL
Intervention: In vitro disaccharidase activity measurement
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: In vivo hydrolysis of lactose, sucrose, and palatinose
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: In vivo lactase and sucrase deficiency
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Histomorphometric assessment of jejunal biopsy specimens
Number of subjects: 54
Study: 8645051

Group type: EXPERIMENTAL
Intervention: rhGH plus propranolol
Number of subjects: 6

Group type: COMPARATOR
Intervention: rhGH
Number of subjects: 6
Study: 1824248

Group type: EXPERIMENTAL
Intervention: High-dose methotrexate (MTX)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Low-dose methotrexate (MTX)
Number of subjects: 77
Study: 6850612

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus immunotherapy (Nocardia rubra cell wall skeleton, 400 micrograms, intradermal injection weekly for the first month and monthly thereafter)
Number of subjects: 302

Group type: COMPARATOR
Intervention: Chemotherapy (control group)
Number of subjects: 302
Study: 30211721

Group type: EXPERIMENTAL
Intervention: Combined mirror and extracorporeal shock wave therapy (ESWT)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Mirror therapy
Number of subjects: 120

Group type: COMPARATOR
Intervention: Extracorporeal shock wave therapy (ESWT)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional rehabilitation training
Number of subjects: 120
Study: 29364083

Group type: EXPERIMENTAL
Intervention: One-hand cooling (1H)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Two-hand cooling (2H)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cooling jacket (CJ)
Number of subjects: 12

Group type: COMPARATOR
Intervention: No cooling (NC)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Cognitive performance (Stroop Colour-Word test)
Number of subjects: 12
Study: 27321342

Group type: EXPERIMENTAL
Intervention: Saxagliptin (2.5mg/day)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 82
Study: 24331545

Group type: EXPERIMENTAL
Intervention: Low field magnetic stimulation (LFMS), single 20-minute treatment
Number of subjects: 63

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Low field magnetic stimulation (LFMS)
Number of subjects: 63
Study: 22176629

Group type: EXPERIMENTAL
Intervention: Posaconazole 50 mg
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Posaconazole 100 mg
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Posaconazole 200 mg
Number of subjects: 35

Group type: COMPARATOR
Intervention: Simvastatin 40 mg
Number of subjects: 35

Group type: COMPARATOR
Intervention: Midazolam 2 mg
Number of subjects: 35
Study: 20482337

Group type: EXPERIMENTAL
Intervention: Trichomonas prevalence
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Chlamydia prevalence
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Syphilis prevalence
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Gonorrhea prevalence
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Risk factors for trichomonas
Number of subjects: 198
Study: 17373918

Group type: EXPERIMENTAL
Intervention: Hyperhomocysteinaemia (high homocysteine level >15 micromol/L)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Hyperhomocysteinaemia
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Ileal Crohn's disease
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Disease duration of at least 5 years
Number of subjects: 92
Study: 15829804

Group type: COMPARATOR
Intervention: Topical natamycin 5%
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Topical itraconazole 1%
Number of subjects: 100
Study: 12102671

Group type: EXPERIMENTAL
Intervention: Levetiracetam, 500 mg, twice daily
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 10208788

Group type: EXPERIMENTAL
Intervention: Education and support by a nurse during hospital stay and a home visit within a week of discharge
Number of subjects: 179

Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Education and support by a nurse
Number of subjects: 179
Study: 7605860

Group type: EXPERIMENTAL
Intervention: Levosulpiride 25 mg t.d.s. for 4 weeks
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 23
Study: 2369474

Group type: EXPERIMENTAL
Intervention: Intravesical application of cephalotin in saline solution
Number of subjects: 200

Group type: COMPARATOR
Intervention: Saline solution only (control group)
Number of subjects: 200
Study: 454027

Group type: EXPERIMENTAL
Intervention: Autotransfusion
Number of subjects: 113

Group type: COMPARATOR
Intervention: Control
Number of subjects: 113
Study: 31743300

Group type: EXPERIMENTAL
Intervention: Fresh whole blood (FWB)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Fresh frozen plasma (FFP)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 5% human albumin (ALB)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Untreated group
Number of subjects: 30
Study: 31104507

Group type: EXPERIMENTAL
Intervention: galcanezumab 120 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: galcanezumab 240 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study: 27915105

Group type: EXPERIMENTAL
Intervention: Sleep restriction (4h Time in Bed for 4 nights)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sleep deprivation (30h total)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Well-rested (9h Time in Bed)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sleep loss (both partial and total)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visual false memory task
Number of subjects: 0
Study: 25573410

Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnoea
Number of subjects: 213
Study: 24016143

Group type: EXPERIMENTAL
Intervention: Sexual health quality improvement program (SHQIP)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Usual STI clinical care
Number of subjects: 68
Study: 21813191

Group type: EXPERIMENTAL
Intervention: Ankaferd Blood Stopper (ABS)
Number of subjects: 90
Study: 19559427

Group type: EXPERIMENTAL
Intervention: 0.5 mL cyanoacrylate injection (group A)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: 1.0 mL cyanoacrylate injection (group B)
Number of subjects: 91
Study: 17055681

Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Oxcarbazepine (OXC)
Number of subjects: 39
Study: 15118585

Group type: EXPERIMENTAL
Intervention: Laparoscopic and open gastric banding
Number of subjects: 50
Study: 11578673

Group type: EXPERIMENTAL
Intervention: Single daily dosing (SDD) of antidepressants
Number of subjects: 22

Group type: COMPARATOR
Intervention: Multiple daily dosing (MDD) of antidepressants
Number of subjects: 22
Study: 9573431

Group type: EXPERIMENTAL
Intervention: Light social drinkers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moderate social drinkers
Number of subjects: 0
Study: 8147945

Group type: EXPERIMENTAL
Intervention: Nifedipine (60 mg slow release tablet, Aprical long)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 88
Study: 3260059

Group type: EXPERIMENTAL
Intervention: Walking therapy
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Sauna therapy
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control (no specific intervention mentioned)
Number of subjects: 43
Study: 30390443

Group type: EXPERIMENTAL
Intervention: Gonadotropin‐releasing hormone agonist (GnRHa)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study: 26972105

Group type: EXPERIMENTAL
Intervention: Coactivation Group (CG) - where muscle coactivation was increased intentionally.
Number of subjects: 34

Group type: COMPARATOR
Intervention: Non-Coactivation Group (NCG) - control group with no intentional increase in muscle coactivation.
Number of subjects: 34
Study: 26039600

Group type: EXPERIMENTAL
Intervention: Intensive glucose control
Number of subjects: 1791

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 1791
Study: 23782948

Group type: EXPERIMENTAL
Intervention: Whey protein isolate, large isocaloric doses, duration 8 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rice protein isolate, large isocaloric doses, duration 8 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 21744346

Group type: EXPERIMENTAL
Intervention: Ischemic Preconditioning (IP) - 10 min ischemia, 10 min reperfusion
Number of subjects: 160

Group type: COMPARATOR
Intervention: Intermittent Portal Clamping (IPC) - 15 min ischemia, 5 min reperfusion
Number of subjects: 160
Study: 19332353

Group type: EXPERIMENTAL
Intervention: Catheter-based renal sympathetic denervation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (non-treated patients)
Number of subjects: 50
Study: 16384587

Group type: EXPERIMENTAL
Intervention: Self-instructional technique involving self-cueing to recall specific autobiographical experiences
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (Group 1) without training
Number of subjects: 30
Study: 15176685

Group type: EXPERIMENTAL
Intervention: Clarithromycin 250 mg b.i.d. for 8 weeks (Arm A)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Clarithromycin 250 mg t.i.d. (Arm B)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo dextrose tablets (Arm C)
Number of subjects: 30
Study: 11528262

Group type: EXPERIMENTAL
Intervention: Topical betaxolol
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Topical dorzolamide
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Topical apraclonidine
Number of subjects: 22
Study: 9437230

Group type: EXPERIMENTAL
Intervention: GLP-1 (400 micrograms buccal tablet)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Fasting state
Number of subjects: 16
Study: 8279693

Group type: EXPERIMENTAL
Intervention: 50 micrograms.kg‐1 ondansetron
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 100 micrograms.kg‐1 ondansetron
Number of subjects: 100

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Lysin acetylsalicylate (LAS)
Number of subjects: 100
Study: 3828171

Group type: EXPERIMENTAL
Intervention: Closed-loop computer system delivering sodium nitroprusside infusion
Number of subjects: 60

Group type: COMPARATOR
Intervention: Manual control by nursing staff
Number of subjects: 60
Study: 29871619

Group type: EXPERIMENTAL
Intervention: Savings-led economic empowerment through youth development accounts (YDA)
Number of subjects: 1260

Group type: EXPERIMENTAL
Intervention: Savings-led economic empowerment through youth development accounts (YDA) + Multiple Family Groups (MFG)
Number of subjects: 1260

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 1260
Study: 26682533

Group type: EXPERIMENTAL
Intervention: Coke Zero
Number of subjects: 209

Group type: COMPARATOR
Intervention: Water
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Coke Zero and Water
Number of subjects: 209
Study: 25342385

Group type: EXPERIMENTAL
Intervention: 99mTc-MIP-1404
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 99mTc-MIP-1405
Number of subjects: 12

Group type: COMPARATOR
Intervention: Standard-of-care bone scanning
Number of subjects: 12
Study: 23137508

Group type: COMPARATOR
Intervention: HFpEF (n = 81)
Number of subjects: 300

Group type: COMPARATOR
Intervention: HFpEF (n = 50)
Number of subjects: 300
Study: 19763665

Group type: EXPERIMENTAL
Intervention: Early onset schizophrenia (EOS) patients
Number of subjects: 10

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Patients with other non-affective psychoses
Number of subjects: 10
Study: 18600411

Group type: EXPERIMENTAL
Intervention: (99m)Tc-DTPA aerosol scintigraphy
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 21
Study: 16084925

Group type: EXPERIMENTAL
Intervention: Facilitated programme supported by a trained external facilitator
Number of subjects: 22
Study: 12593178

Group type: EXPERIMENTAL
Intervention: Patient education programs for asthma; details on dosage and duration not specified.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Education programs in COPD including self-management; details on dosage and duration not specified.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cost effectiveness of education programs for asthmatics; details on dosage and duration not specified.
Number of subjects: 0